Page 88 - Chief Development News Today

Parallel Appoints Jeremy Kunicki as Chief Financial Officer Kunicki brings public company leadership from a global retail and pharmacy chain as Parallel prepares to go public via SPAC News provided by Share this article Share this article ATLANTA and WEST PALM BEACH, Fla., March 1, 2021 /PRNewswire/ -- Parallel, one of the largest privately held, vertically integrated, multi-state cannabis companies in the world, today appointed Walgreens veteran Jeremy Kunicki as its Chief Financial Officer (...

by Erin Dunigan for Presbyterian Foundation | Special to Presbyterian News Service the Rev. Dr. Craig Howard JEFFERSONVILLE, Indiana — When the Rev. Dr. Craig Howard describes the journey that led him to become the Foundation’s newest Ministry Relations Officer, he says that it all began with his work as an insurance agent. Last month, Howard joined the Presbyterian Foundation as the Ministry Relations Officer serving the Central Region, which includes Kansas, Missouri, Illinois, Indiana...

The company is looking to boost plant energy efficiency by 30% Abu Dhabi’s Tabreed has launched a new initiative called ‘Wet bulb Forecasting.’ It makes use of AI (artificial intelligence) to more accurately forecast customer demand. Image Credit: File photo Dubai: Abu Dhabi’s Tabreed has launched a new initiative called ‘Wet bulb Forecasting.’ It makes use of AI (artificial intelligence) to more accurately forecast customer demand for the next 24 hou...

Operator Good morning, and welcome to Ionis Pharmaceuticals Fourth Quarter and Full Year 2020 Financial Results conference call. [Operator Instructions] At this time, I would like to turn the call over to Wade Walke, Vice President of Investor Relations to lead off the call. Please begin. D. Wade Walke -- Vice President, Investor Relations Thank you, Tom. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to find the press release and related financial ta...

Operator Welcome to the Fate Therapeutics Fourth Quarter 2020 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section on Fates website at fatetherapeutics.com. As a reminder, todays call is being recorded. I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics. The floor is yours. Scott Wolchko -- President and Chief Executive Officer Thank you. Good afternoon, a...

Gov. Parson announces five appointments to boards and commissions; Columbian named to Mental Health Commission KMIZ JEFFERSON CITY, Mo. (KMIZ) Gov. Mike Parson named a Columbian to the Mental Health Commission and four other appointments to various boards and commissions and filled one county office vacancy. The governor appointed Brian Neuner to the Mental Health Commission. The release states, Neuner currently serves as the Chief Development and Marketing Officer for Special Olympics of Misso...

Operator Good afternoon, ladies and gentlemen, thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter and Full Year 2020 Financial Results Call. Please be advised that todays call is being recorded. I would now like to hand the conference over to your host for today, Chau Cheng, CytomXs Vice President, Investor Relations and Corporate Communications. Please go ahead. Chau Cheng -- Vice President, Investor Relations and Corporate Communications Thank you, Victor. Good afte...

Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Genmab A/S (NASDAQ: GMAB) Q4 2020 Earnings Call [Operator Instructions] During this telephone conference you may be presented with forward-looking statements that include words such as believes, anticipates, plans or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. Genmab...

Share this article Share this article PERTH, Australia and NEW YORK, Feb. 23, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced the appointment of Glenn Noronha, PhD, as Chief Development Officer. Dr. Noronha will oversee the Companys translational clinical development, regulatory, manufacturing and preclinical development activities as it a...

Decama Capital Ltd Kickstarts Green Energy Offering with Chief Development Officer Appointment USA - English Share this article LONDON and TEL AVIV, Israel, Feb. 23, 2021 /PRNewswire/ -- Decama Capital Ltd (TASE: DCMA), a leading Israeli investment company headquartered in the UK and listed on the Tel Aviv Stock Exchange, is delighted to announce the recent appointment of Professor Lior Elbaz as Chief Development Officer. The appointment is an integral step in the companys expansion strategy ...